Apollo Life Sciences completes data collection for psoriasis trial

By Angela McDaniels

Seattle, Jan. 23 - Apollo Life Sciences Ltd. said it has collected all data for its phase 1b clinical trial of its topical psoriasis cream ALS-00T2-0501.

No significant adverse events were reported during the 20-subject trial, which was designed to test the safety of the drug, according to a company news release.

Healthy subjects and patients with mild to moderate chronic plaque-type psoriasis - the most common form of psoriasis - received a single application of the cream in the first two stages of the trial. The third stage was double-blind, placebo-controlled and involved nine applications of the cream to patients over a 21-day period.

Data from the trial is being forwarded to independent contract research organization Datapharm Australia for database entry, verification and statistical analysis. Final results are expected to be available in early April.

Apollo said it believes that the cream, which is a TNF blocker, will have advantages over existing injection-based treatments, which can suppress the immune system, and that patients will prefer a cream to injections.

Apollo Life Sciences is based in Beaconsfield, Australia, and creates, manufactures and markets therapeutics based on the use of human proteins.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.